AM

Amgen

Every trial this sponsor leads in the registry, and everything it has published.

980All trials
Recruiting41
Recruited51
Not yet recruiting5
Completed741
Stopped136
Other6

97 active · 10% of this sponsor’s registry footprint

Oncology42 trials
Metabolic/Endocrine/Nutrition22 trials
Neurology7 trials
Immunology & Inflammation6 trials
Cardiovascular4 trials
Pain & Musculoskeletal3 trials
Respiratory2 trials
Dermatology1 trial

Not shown above: 3 Phase 1 healthy-volunteer trials and 5 trials whose condition matched no therapy area.

Trials by phase

Phase 1319
Phase 2262
Phase 3305
Phase 483
Unphased11

Pipeline by phase · 34 drugs in active development

Phase 3 · 20 drugs

Maridebart Cafraglutide14 trials · 8 recruitingest. Nov 2026
Tarlatamab12 trials · 3 recruitingest. Dec 2026
Xaluritamig (AMG 509)8 trials · 6 recruitingest. Feb 2027
Blinatumomab5 trialsest. Nov 2027
Apremilast4 trials · 3 recruitingest. Mar 2028
Olpasiran3 trials · 2 recruitingest. Mar 2028
Sotorasib3 trials · 2 recruitingest. Dec 2026
ABP 2342 trialsest. Dec 2026

Phase 2 · 2 drugs

Anvumetostat4 trialsest. Oct 2026
AMG 7322 trials · 1 recruitingest. Jan 2027

Phase 1 · 8 drugs

AMG 6912 trials · 1 recruitingest. Mar 2027
AMG 1271 trial · 1 recruitingest. Oct 2027
AMG 4101 trial · 1 recruitingest. Apr 2028
AMG 4361 trial · 1 recruitingest. Jul 2028
AMG 5131 trialest. Sept 2026
COC1 trialest. Nov 2026
Tambotatug Pelitecan (YL201)1 trialest. Jun 2031
ZL-13101 trial · 1 recruitingest. May 2028

Phase 4 · 4 drugs

inebilizumab8 trials · 3 recruitingest. Apr 2027
Denosumab3 trialsest. Jan 2027
Avacopan2 trials · 1 recruitingest. Jul 2027
Evolocumab2 trialsest. May 2027

Active trials only, code names and brands merged. 741 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 4 of 10 curated

Type 2 diabetes (Endocrinology)6 trials · 2 recruiting · 2 drugs0.6% of landscape
Non-small cell lung cancer (Oncology)4 trials · 1 recruiting · 3 drugs0.3% of landscape
Obesity (Metabolic & Nutrition)3 trials · 2 recruiting · 1 drug0.3% of landscape
Breast cancer (Oncology)1 trial · 1 drug<0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon